TrialPloS one2026

Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial.

Daniel Franjic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.